Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Nerdwallet Inc (NRDS) Price & Performance

Cassava Sciences IncTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Nerdwallet Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Nerdwallet Inc trades at $9.53 (market cap $625.17M). The key difference: Nerdwallet Inc is far larger — about 13.1× Cassava Sciences Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNANRDS
Market Cap
$47.75M$625.17M
Sector
HealthFinancials
52-Week High
$4.64$15.93
52-Week Low
$0.87$7.58
Enterprise Value
-$34.93M$539.47M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Nerdwallet Inc

NRDS trades at $9.76, down 0.41% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue of $197 million, up 6% year-over-year, though EPS missed estimates. Valuation ratios appear attractive with a P/E of 10.87 and P/S of 0.81, while profitability metrics like an 18.16% ROE and 93.5% gross margin remain strong. Recent news highlights analyst optimism for a 27.9% upside potential.

The outlook is positive due to solid fundamentals and growth in personal loans and deposit accounts, offsetting SEO pressures. Risks include execution in shifting business models and competitive threats. With 66.7% of analysts rating it Buy and a consensus bullish stance, the stock presents a growth opportunity amid manageable risks.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS